XML 65 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2012
       
 Three Months Ended March 31,
 Licensee
 
 Product Name
 
2012
 
2011
 Genentech, Inc. (Genentech)
 
 Avastin®
 
30%
 
27%
   
 Herceptin®
 
33%
 
30%
   
 Lucentis®
 
14%
 
11%
             
 Elan Corporation, Plc (Elan)
 
 Tysabri®
 
15%
 
12%